A new study funded by Novo Nordisk, the manufacturer of the Vigobi drug, has shown that the drug is an effective treatment for individuals with type 2 diabetes and heart failure who are obese. The study involved 616 participants from various countries around the world, with one group receiving the Vigobi injection while the other received a placebo.
Those who received Vigobi showed significant improvements in weight loss, reduction of heart failure symptoms, increased physical endurance, and improvements in biomarkers for inflammation. The results suggest that Vigobi is a safe and effective treatment for a diverse population, including complex patients with diabetes.
Dr. Michael Kosybrod, head of the research team, noted that while weight loss may play a role in the positive outcomes seen with Vigobi, it does not account for all of the benefits. The drug has been shown to be particularly beneficial for patients with diabetes, who are often challenging to treat.
Vigobi is now available in Israel at a monthly cost of NIS 1,250 for the recommended dose. The drug is administered in gradually increasing doses, with many patients likely needing to take it for an extended period if not for life. This new treatment offers hope for a population of patients who previously had limited options for managing their condition.
Heart failure is often linked to obesity and can significantly impair a person’s ability to carry out everyday tasks. Those affected may experience fatigue, difficulty breathing and may even require oxygen. In severe cases, heart failure can lead to hospitalization, disability and death.
A recent study has found that individuals with type 2 diabetes and heart failure who were obese responded well to Vigobi injection.
The study involved 616 participants from various countries around the world where one group received the Vigobi injection while another group received a placebo.
The results showed that those who received Vigobi experienced fewer side effects compared to those who received placebo.
They also experienced significant improvements in weight loss reduction of heart failure symptoms increased physical endurance and biomarkers for inflammation.
Dr Michael Kosybrod said while weight loss may have played a role in some positive outcomes seen with Vigobi but it does not account for all benefits.
